Payment overview · 2025
General Payments
$686.58
20 reported records · 13 companies
Healthcare provider profile · identity verified
Rachel Marie Sullivan, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · REDDING, CA · NPI 1346529310
Verified facts
What the public records show
CMS Open Payments records show Rachel Marie Sullivan, M.D. received $686.58 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 28.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $195.21 | 28.4% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $115.33 | 16.8% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $90.34 | 13.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.88 | 6.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.62 | 6.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.08 | 5.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.65 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.28 | 3.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.98 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.21 | 3.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.18 | 3.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.41 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.41 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $686.58 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $154.39 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $115.33 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $90.34 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.62 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $42.62 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.08 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.08 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.08 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $32.65 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.26 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.26 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
143 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 630 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 617 | 159 |
| Lisinopril | Lisinopril | 365 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 96 |
| Losartan Potassium | Losartan Potassium | 319 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 92 |
| Omeprazole | Omeprazole | 241 | 66 |
| Gabapentin | Gabapentin | 239 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 215 | 42 |
| Metformin Hcl | Metformin Hcl | 185 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 45 |
| Synthroid | Levothyroxine Sodium | 143 | 34 |
| Eliquis | Apixaban | 142 | 26 |
| Alprazolam | Alprazolam | 139 | 42 |
| Simvastatin | Simvastatin | 138 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 43 |
| Trazodone Hcl | Trazodone Hcl | 135 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 29 |
| Alendronate Sodium | Alendronate Sodium | 124 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 33 |
| Furosemide | Furosemide | 113 | 32 |
| Sertraline Hcl | Sertraline Hcl | 110 | 31 |
| Potassium Chloride | Potassium Chloride | 109 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 29 |
| Meloxicam | Meloxicam | 95 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 95 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 20 |
| Ezetimibe | Ezetimibe | 86 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 25 |
| Ozempic | Semaglutide | 79 | 14 |
| Benazepril Hcl | Benazepril Hcl | 78 | 20 |
| Estradiol | Estradiol | 77 | 32 |
| Atenolol | Atenolol | 68 | 18 |
| Jardiance | Empagliflozin | 68 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 16 |
| Celecoxib | Celecoxib | 66 | 17 |
| Carvedilol | Carvedilol | 63 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 14 |
| Pregabalin | Pregabalin | 60 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 16 |
| Tramadol Hcl | Tramadol Hcl | 56 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 55 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Montelukast Sodium | Montelukast Sodium | 51 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Baclofen | Baclofen | 44 | suppressed |
| Xarelto | Rivaroxaban | 43 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 14 |
| Enalapril Maleate | Enalapril Maleate | 40 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Irbesartan | Irbesartan | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 19 |
| Bupropion Xl | Bupropion Hcl | 35 | 13 |
| Diazepam | Diazepam | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Lorazepam | Lorazepam | 31 | 17 |
| Spironolactone | Spironolactone | 31 | 11 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Levoxyl | Levothyroxine Sodium | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Yuvafem | Estradiol | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $686.58 · 20 records | ABBVIE INC. | ABRYSVO, AREXVY, COMIRNATY, CREON, Cologuard Collection Kit, Da Vinci Surgical System, Dexcom G6 Transmitter, EVENITY, General - Pain Management, JARDIANCE, LEQVIO, LINZESS, Ozempic, PENMENVY, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error